Opinion Review
Copyright ©The Author(s) 2022.
World J Nephrol. Jan 25, 2022; 11(1): 1-12
Published online Jan 25, 2022. doi: 10.5527/wjn.v11.i1.1
Table 1 Studies about viruses in renal cell carcinoma
Ref.
Study type
Analyzed specimens
Virus investigated
Analysis method
Positive specimens
No. of cases and tumor type
No. of controls and tissue type
No. of positive cases and tumor type
No. of positive controls and tissue type
Kim et al[18], 2005Retrospective73 RCC (22 clear cell; 18 papillary; 20 chromophobe; 10 sarcomatoid; 3 oncocytoma)18 non-neoplastic kidneysEBVEBER-ISH and PCRs (for EBNA-1 and EBNA-3C)5/73 (all sarcomatoid histology) (EBER-ISH)2; 4/73 (all sarcomatoid histology) showed amplification of EBNA-10/18
Neirynck et al[17], 2012Case report1 RCC11 peritumoral tissueBKVIHC (for SV40 T antigen)65%-70% neoplastic cells< 1% non-neoplastic cells
Salehipoor et al[19], 2012Retrospective49 RCC16 non-neoplastic kidneysHPV; EBV; BKV; JCVNested PCR (virus DNA)7/49 HPV (5 clear cell; 1 chromophobe 1 mixed type) 0 EBV, BKV JCV0/16
Bulut et al[16], 2013Retrospective50 RCC45 non-neoplastic kidneysBKVNested PCR (BKV DNA) and RT-PCR (BKV mRNA)10/50 (Nested PCR) 8/50 (RT-PCR)2/45 non neoplastic kidneys (nested PCR, RT-PCR)
Farhadi et al[20], 2014Retrospective122 RCC (77 conventional; 26 papillary; 14 chromophobe; 1 collecting duct; 4 unclassified)96 peritumoral tissues, 19 non-neoplastic kidneysHR-HPVNested PCR (HR-HPV DNA). IHC (for p16INK4a and L1 Capsid Protein); CSAC-ISH37/122 (17 clear-cell; 13 papillary; 4 chromophobe; 3 unclassified) (PCR). 24/118 (IHC for p16INK4a3) 0/118 (IHC for L1 capsid protein); 18/122 (CSAC-ISH)4/96 peritumoral tissues; 0/19 non-neoplastic kidneys (PCR); 16/94 peritumoral tissue (IHC for p16INK4a); 0/94 peritumoral tissue (IHC for L1 capsid protein); NA (CSAC-ISH)
Table 2 Studies reporting the relationship between chronic viral infections and the occurrence of renal cell carcinoma
Ref.
Study type
Type of chronic viral infection
Study population
RCC histology
Mean age (yr)
Aim
Main results/conclusions
Gaughan et al[43], 2008Case seriesHIV infection9 HIV-associated RCC12 papillary, 1 collecting duct, 6 clear cell48To describe the risk factors, clinical findings, pathology, and response to therapy in RCC patients infected with HIVThe clinical presentation and behavior of RCC in patients with HIV infection appeared similar to that of the HIV-negative population and that chronic immunosuppression plays a lesser role than age and exposure to risk factors
Gordon et al[38], 2010Retrospective studyHCV infection67063 HCV-tested patients: 3057 HCV+ and 64006 HCV-17 RCC HCV+: 8 clear cell, 6 papillary, 2 mixed clear cell/papillary, 1 undifferentiated/other; 117 HCV-: 92 clear cell, 43 papillary, 9 mixed clear cell/papillary, 26 undifferentiated/other54 in HCV+, 63 in HCV-To determine whether HCV infection confers an increased risk for developing RCCRCC was diagnosed in 0.6% (17/3057) of HCV+ and 0.3% (117/64006) of HCV- patients. HCV infection confers a risk for the development of RCC: Overall HR for RCC among HCV patients 1.77 (95% confidence interval, 1.05-2.98; P = 0.0313)
Wiwanitkit[42], 2011Bioinformatics analysisHCV infectionNANANATo assess the cause–outcome relationship between HCV infection and RCC using the bioinformatics network analysis techniqueThere might be a cause–outcome relationship between HCV infection and RCC via NY-REN-54 (the only one common protein)
Gonzalez et al[39], 2015Prospective studyHCV infection140 RCC and 100 colon cancer patients (control)NA56.7 in RCC patients with viremia, 61.8 in aviremic patientsTo determine whether chronic HCV is associated with an increased risk of RCC11/140 RCC and 1/100 colon cancer patients were HCAB+. Of the HCAB+ patients, 9/11 RCC and 0/1 controls had detectable HCV RNA. In the multivariable logistic regression analysis, being HCV RNA positive was a significant risk factor for RCC (P = 0.043)
Wijarnpreecha et al[40], 2016Systematic review and meta-analysisHCV infection196826 patients from 7 observational studies (4 cohort and 3 case-control studies). Individuals without HCV infection were used as comparators in cohort studies, individuals without RCC as comparators in the cross-sectional and case-control studiesNANA2To assess the risk of RCC in patients with HCV infectionSignificantly increased risk of RCC in HCC+ with the pooled risk ratio of 1.86 (95%CI: 1.11-3.11)
Ong et al[44], 2016Case seriesHIV infection7 HIV-associated RCC15 clear cell, 1 papillary, 1 unknown56To report presentation, management and outcomes of RCC patients with HIV infectionRCC patients with HIV infection should be offered all treatment options in the same manner as the general population
Tsimafeyeu et al[41], 2020Retrospective studyHCV infection44 mRCC patients: 22 HCV+, 22 HCV-Clear cell62 in mRCC HCV+, 63 in mRCC HCV-To evaluate Nivolumab efficacy and safety in mRCC patients with or without chronic HCV infection (OS primary endpoint, PFS, ORR and rate of grade 3–4 adverse events secondary endpoints)HCV-infected patients had significantly longer OS (27.5 vs 21.7, P = 0.005) and PFS (7.5 vs 4.9, P = 0.013), no difference in ORR. Grade 3–4 adverse events were observed in 5 (23%) HCV+ patients and in 3 (14%) HCV- patients